Latest News

Ovarian Cancer - Personalised/Precision Medicine - Anticancer Agents

Veliparib Combination Plus Maintenance Extends PFS For Advanced Serous Ovarian Carcinoma

  • 15 Oct 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Use of veliparib alongside chemotherapy and continuing with the PARP inhibitor as a maintenance therapy has improved progression-free survival for advanced ovarian cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Veliparib Combination Plus Maintenance Extends PFS For Advanced Serous Ovarian Carcinoma

Hepatobiliary Cancers - Personalised/Precision Medicine - Anticancer Agents

Targeted Agent May Improve Survival For IDH1-Mutated Advanced Cholangiocarcinoma

  • 14 Oct 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Advanced cholangiocarcinoma patients with an IDH1 mutation may benefit from a targeted therapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Targeted Agent May Improve Survival For IDH1-Mutated Advanced Cholangiocarcinoma

Small Cell Lung Cancer - Anticancer Agents - Immunotherapy

CASPIAN PROs Support Durvalumab Use For Extensive-Stage SCLC

  • 11 Oct 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

The addition of durvalumab to etoposide–pemetrexed helps maintain quality of life in patients with extensive-stage small-cell lung cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof CASPIAN PROs Support Durvalumab Use For Extensive-Stage SCLC

Colon and Rectal Cancer - Personalised/Precision Medicine - Anticancer Agents

BEACON CRC Triple Regimen Boosts BRAF V600E-Mutated Metastatic CRC Survival

  • 10 Oct 2019
  • Author : ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

Encorafenib, cetuximab and binimetinib show promise as a combination regimen for patients with previously treated metastatic colorectal cancer positive for the BRAF V600E mutation...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof BEACON CRC Triple Regimen Boosts BRAF V600E-Mutated Metastatic CRC Survival

Oesophageal Cancer - Anticancer Agents - Immunotherapy

ATTRACTION-3 Confirms Nivolumab OS Benefit For Advanced Oesphageal Carcinoma

  • 09 Oct 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Patients with previously treated advanced oesophageal squamous cell carcinoma survive longer with nivolumab than with a second line of chemotherapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof ATTRACTION-3 Confirms Nivolumab OS Benefit For Advanced Oesphageal Carcinoma

Prostate Cancer - Anticancer Agents

Cabazitaxel Benefit Demonstrated For metastatic CRPC Patients

  • 08 Oct 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Patients with metastatic castration-resistant prostate cancer have better outcomes with third-line cabazitaxel than with receipt of a second androgen signalling-targeted agent...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Cabazitaxel Benefit Demonstrated For metastatic CRPC Patients

Ovarian Cancer - Personalised/Precision Medicine - Anticancer Agents

PAOLA-1 Supports Olaparib–Bevacizumab Maintenance For HRD-Positive Advanced Ovarian Cancer

  • 07 Oct 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Adding olaparib to maintenance bevacizumab extends progression-free survival for women with HRD-positive advanced ovarian cancer who have responded to first-line platinum-based chemotherapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof PAOLA-1 Supports Olaparib–Bevacizumab Maintenance For HRD-Positive Advanced Ovarian Cancer

Prostate Cancer - Personalised/Precision Medicine - Anticancer Agents

Olaparib May Have PROfound Effect On mCRPC

  • 03 Oct 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Men with metastatic castration-resistant prostate cancer with HRD gene alterations may benefit from second-line or later olaparib therapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Olaparib May Have PROfound Effect On mCRPC

Non-Small Cell Lung Cancer - Personalised/Precision Medicine - Anticancer Agents

FLAURA: First-Line OS Benefit Confirmed For Advanced EGFR-Mutated NSCLC

  • 02 Oct 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Front-line osimertinib offers a significant overall survival advantage for patients with advanced EGFR-mutated non-small-cell lung cancer compared with gefitinib or erlotinib...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof FLAURA: First-Line OS Benefit Confirmed For Advanced EGFR-Mutated NSCLC

Breast Cancer - Anticancer Agents - Immunotherapy

Pembrolizumab Shows Early Triple-Negative Breast Cancer Potential

  • 01 Oct 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Use of neoadjuvant pembrolizumab with chemotherapy increases the likelihood of a pathological complete response in women with early-stage triple-negative breast cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Pembrolizumab Shows Early Triple-Negative Breast Cancer Potential

Breast Cancer - Anticancer Agents

Abemaciclib Plus Fulvestrant Supported For HR-Positive, HER2-Negative Advanced Breast Cancer

  • 30 Sep 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Adding a CDK4/6 inhibitor to fulvestrant treatment improves breast cancer overall survival for women who have progressed during endocrine therapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Abemaciclib Plus Fulvestrant Supported For HR-Positive, HER2-Negative Advanced Breast Cancer

Non-Small Cell Lung Cancer - Immunotherapy

CheckMate 227 Further Supports First-Line Nivolumab–Ipilimumab For Advanced NSCLC

  • 29 Sep 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

For advanced non-small-lung cancer patients with PD-L1 expression of 1% or higher, nivolumab plus ipilimumab offers better overall survival than chemotherapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof CheckMate 227 Further Supports First-Line Nivolumab–Ipilimumab For Advanced NSCLC

Melanoma - Immunotherapy

Advanced Melanoma Nivolumab–Ipilimumab Survival Benefit Lasts For 5 years

  • 28 Sep 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

First-line nivolumab plus ipilimumab significantly extends survival in advanced melanoma compared with either agent given as monotherapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Advanced Melanoma Nivolumab–Ipilimumab Survival Benefit Lasts For 5 years

Complications/Toxicities of Treatment - Radiation Oncology

Hyperbaric Oxygen Combats Radiation-Induced Cystitis Symptoms

  • 23 Sep 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

The RICH-ART study points to a benefit from hyperbaric oxygen for patients who experience late cystitis after pelvic radiotherapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Hyperbaric Oxygen Combats Radiation-Induced Cystitis Symptoms

Surgical Oncology - Radiation Oncology

Local Therapy Boosts Metastatic Intrahepatic Cholangiocarcinoma Survival

  • 20 Sep 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Adding liver-directed surgery or radiotherapy to chemotherapy improves overall survival for patients with metastatic intrahepatic cholangiocarcinoma...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Local Therapy Boosts Metastatic Intrahepatic Cholangiocarcinoma Survival